IL33 rs10067777: Understanding Genetic Links to Allergic Rhinitis
The rs10067777 variant is a single nucleotide polymorphism located within the IL33 gene. It is statistically associated with an increased predisposition to allergic rhinitis and atopic sensitization in certain populations.
What each genotype means
Typical IL33 expression profile
This genotype represents the common genetic state at this position in the IL33 gene. Research indicates that variants in this region may influence IL33 expression levels, which are involved in immune responses, but the specific functional impact of this genotype remains a subject of ongoing study.
This is a common genotype observed across multiple ancestral populations.
Intermediate regulatory variant carrier
Carrying one copy of the G allele at this position may be associated with differences in how the IL33 gene is regulated. Because IL33 plays a role in type 2 immune responses, this variant is studied for its potential link to allergic traits, though the evidence for this specific SNP's clinical impact is currently limited.
This heterozygous genotype is found in a significant portion of the population, with frequencies varying by ancestry.
Potential regulatory variant carrier
This genotype involves two copies of the G allele, which has been investigated in the context of IL33-related immune regulation. While some variants in the IL33 gene are linked to allergic rhinitis and atopic sensitization, the clinical significance of this specific genotype is not fully established and should be interpreted with caution.
This genotype is less common than the homozygous A state but is present in both European and African ancestral populations.
What is rs10067777?
The variant rs10067777 is a single nucleotide polymorphism (SNP) situated within the IL33 gene. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. This specific variant is classified as an intronic regulatory polymorphism, meaning it resides in a non-coding region of the gene that helps control how the gene is expressed. Because it is located in a regulatory area, researchers investigate whether it influences the amount of IL-33 protein produced by the body. By studying such variants, scientists aim to understand the genetic architecture of complex immune-related traits. While the variant itself does not code for a protein, its position suggests it may act as a switch or a dial, potentially modulating the activity of the IL33 gene in response to environmental triggers.
The Role of the IL33 Gene
The IL33 gene provides instructions for making a protein called interleukin-33, which acts as an 'alarmin' within the immune system. When cells are damaged or stressed, they release IL-33 to alert the immune system, triggering a protective response. This protein is a potent inducer of type 2 immune responses, which are essential for fighting parasites but can also drive allergic inflammation when overactive. IL-33 signals through its receptor, ST2, which is found on various immune cells, including T helper 2 (Th2) cells and innate lymphoid cells. Because of its central role in initiating inflammation, the IL33 gene is a major focus in research regarding asthma, atopic dermatitis, and allergic rhinitis. Understanding how genetic variants like rs10067777 affect this gene helps researchers map the pathways that lead to chronic inflammatory conditions.
Research and Evidence Strength
The association between rs10067777 and allergic conditions is supported by evidence from genome-wide association studies (GWAS). These studies identify statistical correlations between specific genetic markers and traits across large groups of people. For rs10067777, the evidence is currently considered limited. While some studies suggest a link to allergic rhinitis and atopic sensitization, the functional consequences of this specific variant are not fully understood. It is important to note that genetic associations are not the same as direct causation; having a particular genotype does not guarantee the development of an allergy. Many factors, including environmental exposures and other genetic variants, contribute to the development of allergic diseases. Current research continues to explore how regulatory variants in the IL33 locus might alter gene expression levels in airway tissues, but more studies are needed to confirm the clinical significance.
Population Frequency
The frequency of the rs10067777 variant varies significantly across different ancestral groups. Data indicates that the minor allele frequency is approximately 0.30 in European populations and approximately 0.20 in African populations. These differences highlight the importance of considering ancestry when interpreting genetic data. Because the variant is relatively common in these populations, it is considered a polymorphism rather than a rare mutation. Researchers use these frequency patterns to help determine if a variant is likely to be benign or if it contributes to common, complex traits. Understanding these population-specific frequencies is a standard part of genomic research, helping scientists refine their models of how genetic risk is distributed globally.
What This Information Means for You
Learning about a genetic variant like rs10067777 provides insight into the biological pathways that may influence your immune system. However, it is crucial to understand that this information is for educational purposes only and cannot be used to diagnose or predict the development of allergic rhinitis. Genetic markers are only one piece of a much larger puzzle that includes your environment, lifestyle, and overall health history. If you have concerns about allergies or your immune health, the most effective approach is to consult with a qualified healthcare provider or an allergist. They can evaluate your symptoms, perform clinical tests, and provide personalized medical advice. Never use genetic information to make decisions about your health or to alter any prescribed treatments without first discussing it with your clinician.
How common is this variant?
The minor allele frequency for rs10067777 is approximately 0.30 in European populations and 0.20 in African populations.
Frequently asked questions
Does having the rs10067777 variant mean I will develop allergies?
No, having this variant does not mean you will develop allergies. It is only one of many genetic and environmental factors that contribute to the risk of allergic conditions.
Can I use this genetic information to diagnose allergic rhinitis?
No, genetic variants cannot be used to diagnose allergic rhinitis. Diagnosis should only be performed by a healthcare professional based on clinical symptoms and medical testing.
Is rs10067777 the same as other IL33 variants?
No, rs10067777 is a specific SNP within the IL33 gene. Other variants in the same gene may have different effects on gene expression and disease risk.
Should I change my medication based on my genotype?
You should never change your medication based on genetic information without consulting your doctor or pharmacist. Always discuss any health concerns or genetic findings with a qualified clinician.
Sources & further reading
Educational information only, last refreshed 9/29/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10067777?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IL33
Interleukin-33 promoter variant modulating cytokine expression and predisposition to environmental allergies.
A regulatory SNP near the IL33 locus linked to enhanced IL-33 alarmin expression and risk of allergic rhinitis, peanut allergy, and atopic dermatitis.
Upstream regulatory variant affecting IL-33 expression, linked to asthma and atopic phenotypes.
Variant in IL33 associated with asthma and allergic sensitization.
This variant located near the IL33 gene is associated with an increased risk of nasal polyposis, particularly in patients with eosinophilia.